Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02019004 · ClinicalTrials.gov registry record · Early Phase 1

A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles

A Early Phase 1 study of Wrinkles, sponsored by Northwestern University.

Active
Registry status
Early Phase 1
Development phase
20
Enrollment target
1
Study location

NCT02019004 is a Early Phase 1 study of Wrinkles that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 20 participants, below the 53-participant average among 7 other Wrinkles trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02019004, a Early Phase 1 study of Wrinkles, is active but no longer recruiting, sponsored by Northwestern University.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the effectiveness of Botox® (Onabotulinum Toxin A) versus Xeomin® (incobotulinum toxin A) for the treatment of forehead and glabellar (vertical lines between the eyebrows) wrinkles.

Conditions Studied

Interventions

  • DRUG Incobotulinum Toxin A
  • DRUG Onabotulinum Toxin A

Study Locations (1)

Illinois

  • Northwestern University Department of Dermatology - Chicago

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2013-11
Est. Completion 2025-12
Phase Early Phase 1

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT02019004

The ClinicalTrials.gov registry entry for NCT02019004 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 53-participant average among 7 other Wrinkles trials with a reported enrollment target (62% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Wrinkles appearing as the primary indexed condition, and to 2 interventions - of which Incobotulinum Toxin A is the first listed.

NCT02019004 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT02019004 about?

NCT02019004 is a clinical study titled "A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles". The purpose of this study is to compare the effectiveness of Botox® (Onabotulinum Toxin A) versus Xeomin® (incobotulinum toxin A) for the treatment of forehead and glabellar (vertical lines between the eyebrows) wrinkles.

What is the current status of trial NCT02019004?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2013-11. Estimated completion is 2025-12.

What conditions does trial NCT02019004 study?

This clinical trial studies the following conditions: Wrinkles.

What interventions are being tested in trial NCT02019004?

The interventions under investigation include: Incobotulinum Toxin A (DRUG), Onabotulinum Toxin A (DRUG).

Who is sponsoring clinical trial NCT02019004?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02019004 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wrinkles

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.